BioDelivery Sciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

RALEIGH, N.C.--(Business Wire)--
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that Dr.
Mark A. Sirgo, President & Chief Executive Officer, will be presenting at the
Lazard Capital Markets 6th Annual Healthcare Conference to be held November
17-18, 2009, at The St. Regis Hotel, New York.

BioDelivery Sciences` presentation is scheduled for Tuesday, November 17, at
4:10 PM Eastern Time.

Dr. Sirgo will be providing an update on the October 2009 commercial launch of
ONSOLIS (fentanyl buccal soluble film) as well as an update on BDSI`s product
pipeline, which includes BEMA Buprenorphine and two additional BEMA-formulated
product candidates recently added to the portfolio. Dr. Sirgo will also discuss
anticipated Company milestones for the remainder of 2009 and those expected to
occur in 2010.

The presentation will be webcast live and can be accessed at
www.biodeliverysciences.com. For those who are not available to listen to the
live broadcast, the presentation will be archived.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that
is leveraging its novel and proprietary patented drug delivery technologies to
develop and commercialize, either on its own or in partnerships with third
parties, new applications of proven therapeutics. BDSI is focusing on developing
products to meet unmet needs in the areas of pain management and oncology
supportive care. BDSI`s pain franchise currently consists of two products
utilizing the Company`s patented BEMA buccal soluble film technology: ONSOLIS
(fentanyl buccal soluble film) which was approved by FDA on July 16, 2009, for
the management of breakthrough pain in patients with cancer, eighteen years of
age and older, who are already receiving and who are tolerant to opioid therapy
for their underlying persistent cancer pain, and BEMA Buprenorphine, an
analgesic in Phase 2 clinical development with at least one potential target
indication for the treatment of moderate to severe pain. Additional product
candidates are being developed utilizing the BEMA technology for conditions such
as nausea/vomiting and migraine. The Company is also working with its patented
Bioral cochleate technology to facilitate oral dosing of drugs otherwise given
by intravenous administration. The first product under development using the
technology is Bioral Amphotericin B. The Company`s headquarters is located in
Raleigh, North Carolina. For more information please visit
www.biodeliverysciences.com.

BDSI®, BEMA® and Bioral® are registered trademarks, and ONSOLISTM is a trademark
of BioDelivery Sciences International, Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of
BioDelivery Sciences International, Inc. (the "Company") related thereto
contain, or may contain, among other things, certain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation, statements with
respect to the Company`s plans, objectives, projections, expectations and
intentions and other statements identified by words such as "projects," "may,"
"could," "would," "should," "believes," "expects," "anticipates," "estimates,"
"intends," "plans," or similar expressions. These statements are based upon the
current beliefs and expectations of the Company`s management and are subject to
significant risks and uncertainties, including those detailed in the Company`s
filings with the Securities and Exchange Commission. Actual results may differ
significantly from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties that are
subject to change based on various factors (many of which are beyond the
Company`s control).

ICR, Inc.
Donald Ellis
925-253-1240
donald.ellis@icrinc.com
or
BioDelivery Sciences International, Inc.
Al Medwar
VP, Marketing and Corporate Development
919-582-9050
amedwar@bdsinternational.com

Copyright Business Wire 2009